EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

VEGF-A blockade overcomes liver metastases resistance to chemoimmunotherapy in patients with advanced non-squamous NSCLC

Matthieu Roulleaux-Dugage, Andrey Yurchenko, Sergey Nikolaev, Barzin Nabet, Stéphanie Corgnac, Céline Anquetil, Minu K Srivastava, Velimir Gayevskiy, Virginia McNally, Laura Mezquita, Jean-Luc Perfettini, Severine Mouraud und 6 weitere

Journal for ImmunoTherapy of Cancer · 2026-06 · 14 (6) · e014991

DOI: 10.1136/jitc-2026-014991 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 23.06.2026. Verfasst von Matthieu Roulleaux-Dugage und 17 weiteren Autor:innen. Beteiligte Einrichtung: Laboratoire d'Immunomonitoring, INSERM U1363, Gustave Roussy, Villejuif, France. Hauptthemen laut MEDLINE: Lung Neoplasms, Liver Neoplasms, Carcinoma, Non-Small-Cell Lung, Vascular Endothelial Growth Factor A. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Liver metastases (LMs) confer resistance to immune checkpoint blockade in advanced non-squamous non‐small cell lung cancer (ns‐NSCLC), likely through an immunosuppressive tumor microenvironment (TME). We hypothesized that vascular endothelial growth factor (VEGF)-A blockade, by remodeling the immunosuppressive TME, could restore the benefit of chemoimmunotherapy in LM+ patients. Here, we report the first comparative analysis of chemoimmunotherapy with and without bevacizumab specifically in this population. Experimental design Data were analyzed from the phase III IMpower130 and IMpower150 trials in treatment‐naïve, EGFR/ALK-wild‐type patients with ns‐NSCLC. Treatment arms included chemotherapy (CT), CT plus atezolizumab (CT+immunotherapy (IT)), CT plus bevacizumab (CT+antiangiogenic (AA)), and CT+IT+ AA, with LM as a stratification factor. Survival outcomes were assessed by Kaplan-Meier estimates and multivariate Cox regression analyses. Bulk and single‐cell RNA sequencing data were used to characterize the LM TME.

Results

Among 1,713 patients, 236 (13.8%) presented with LMs. In IMpower130, LM+ patients derived no overall survival (OS) benefit from CT plus IT (CT+IT) compared with CT alone (HR for OS: 1.05; 95% CI 0.63 to 1.73). In contrast, in IMpower150, the addition of bevacizumab to CT+IT (CT+IT+ AA) significantly improved progression-free survival (PFS; HR: 0.49) and OS (HR: 0.52) in LM+ patients—an effect not observed in patients without LM. Baseline transcriptomic exploratory analyses from IMpower150 revealed a myeloid-enriched, lymphocyte-depleted TME. Single-cell RNA sequencing further demonstrated VEGF-A/VEGFR-1/2 crosstalk between macrophages and endothelial cells, as well as an autocrine VEGF-A/VEGFR-1 loop within macrophages.

Conclusion

The addition of bevacizumab to chemoimmunotherapy was associated with improved survival in ns‐NSCLC specifically in patients with LMs. These hypothesis-generating findings suggest that the benefit may stem from disruption of VEGF-A-driven immunosuppressive signaling in the liver, but require prospective confirmation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsLiver NeoplasmsCarcinoma, Non-Small-Cell LungVascular Endothelial Growth Factor AImmunotherapyAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleBevacizumabTumor MicroenvironmentAgedMiddle AgedDrug Resistance, Neoplasm

Stichwörter der Autor:innen

Escape/evasionImmune Checkpoint InhibitorImmunotherapyNon-Small Cell Lung CancerTumor microenvironment - TME

Substanzen

Vascular Endothelial Growth Factor ABevacizumabVEGFA protein, human

Autor:innen und Institutionen

  • Laboratoire d'Immunomonitoring, INSERM U1363, Gustave Roussy, Villejuif, France.
  • Medical Oncology Department, Hôpital Européen Georges Pompidou, Paris, France.
  • Drug Development Department, Gustave Roussy, Villejuif, Paris.
  • Translational Cancer Genomics team, INSERM U981, Gustave Roussy, Villejuif, Île-de-France, France.
  • Computational Sciences Center of Excellence, Genentech, South San Francisco, California, USA.
  • INSERM UMR 1186, Integrative Tumour Immunology and Immunotherapy, Gustave Roussy, Villejuif, France.

Zitieren

APA

Roulleaux-Dugage, M., Yurchenko, A., Nikolaev, S., Nabet, B., Corgnac, S., Anquetil, C., Srivastava, M. K., Gayevskiy, V., McNally, V., Mezquita, L., Perfettini, J. L., Mouraud, S., Massard, C., Besse, B., Loriot, Y., Marabelle, A., Chaput, N., & Auclin, E. (2026). VEGF-A blockade overcomes liver metastases resistance to chemoimmunotherapy in patients with advanced non-squamous NSCLC. Journal for ImmunoTherapy of Cancer, 14(6), e014991. https://doi.org/10.1136/jitc-2026-014991

Vancouver

Roulleaux-Dugage M, Yurchenko A, Nikolaev S, Nabet B, Corgnac S, Anquetil C, et al. VEGF-A blockade overcomes liver metastases resistance to chemoimmunotherapy in patients with advanced non-squamous NSCLC. Journal for ImmunoTherapy of Cancer. 2026;14(6):e014991. doi:10.1136/jitc-2026-014991

BibTeX
@article{RoulleauxDugage2026,
  author = {Roulleaux-Dugage, Matthieu and Yurchenko, Andrey and Nikolaev, Sergey and Nabet, Barzin and Corgnac, Stéphanie and Anquetil, Céline and Srivastava, Minu K and Gayevskiy, Velimir and McNally, Virginia and Mezquita, Laura and Perfettini, Jean-Luc and Mouraud, Severine and Massard, Christophe and Besse, Benjamin and Loriot, Yohann and Marabelle, Aurelien and Chaput, Nathalie and Auclin, Edouard},
  title = {VEGF-A blockade overcomes liver metastases resistance to chemoimmunotherapy in patients with advanced non-squamous NSCLC},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  volume = {14},
  number = {6},
  pages = {e014991},
  doi = {10.1136/jitc-2026-014991}
}
Kostenlos starten →